Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. NeuBase Therapeutics Inc.’s current trading price is -89.14% away from its 52-week high, while its distance from the 52-week low is 98.35%. The stock’s price range over this period has fluctuated between $0.61 and $11.05. The company, operating within the financial sector, had a trading volume of approximately 0.63 million for the day, which was noticeably lower than the average daily share volume of 2.38 million over the last 3 months.
The stock price for NeuBase Therapeutics Inc. (NBSE) currently stands at $1.20. The stock experienced a substantial increase in the last session, hitting $1.2612 after starting at $1.26. The stock’s lowest price was $1.15 before closing at $1.30.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The market performance of NeuBase Therapeutics Inc.’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $11.05 on 09/19/22, while the lowest value for the same duration was $0.61 on 08/18/23.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
NeuBase Therapeutics Inc. (NBSE) has experienced a quarterly decline of -55.56% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.86M and boasts a workforce of 37 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.2052, with a change in price of -1.4260. Similarly, NeuBase Therapeutics Inc. recorded 1,513,618 in trading volume during the last 100 days, posting a change of -54.30%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for NBSE stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
NBSE Stock Stochastic Average
Today, NeuBase Therapeutics Inc.’s raw stochastic average for the past 50 days stands at 23.29%, indicating a rise from the raw stochastic average of the last 20 days, which was 22.53%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 25.64% and 26.03% respectively.
NBSE Stock Price Performance Analysis
Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. This year’s metric has recorded a Price decrease of -68.45%. However, over the past six months, we’ve seen a stronger performance of -68.75%. The price of NBSE fallen by 79.10% over the last 30 days. And in the last five days, it has fallen by -8.40%.
